

EDITORIAL

- Ciencia rápida y Coronavirus

ARTÍCULOS ORIGINALES

- Infección invasiva por *Candida spp.* En pacientes inmunocomprometidos: Descripción de curso clínico experiencia diagnóstica, manejo y seguimiento en centro de alta complejidad
- Panorama de resistencia antimicrobiana de los aislamientos urinarios de pacientes adultos en los servicios de urgencias de Manizales, Caldas, durante el 2018
- linfopenia y riesgo de infecciones nosocomiales en ancianos en una institución de salud de Bogotá, Colombia - estudio de casos y controles
- volumen plaquetario medio como predictor de la mortalidad en pacientes con sepsis: revisión sistemática y metanálisis
- Uso compasivo de tigeciclina intraventricular en pacientes con ventriculitis causada por *Enterococcus faecium*. Reporte de seis casos pediátricos
- Una aproximación a la tuberculosis resistente a isoniazida: ¿un problema subestimado en Colombia?

REVISIONES INVITADAS

- A new emerging zoonotic virus of concern: the 2019 novel Coronavirus
- Fast Epidemiology

CASOS CLÍNICOS

- Bacteriemia por *Lactococcus garvieae*: primer caso en Colombia
- Tuberculosis y una *Gemella spp.*: Una combinación indeseable

A new emerging zoonotic virus of concern: the 2019 novel Coronavirus (COVID-19)

José Millán-Oñate¹, Alfonso J. Rodríguez-Morales^{2,*}, German Camacho-Moreno³, Henry Mendoza-Ramírez⁴, Iván Arturo Rodríguez-Sabogal⁵, Carlos Álvarez-Moreno⁶

Abstract

We review here the origin, outbreak characteristics and main epidemiological features of the novel Coronavirus (2019nCoV) responsible of a new coronavirus disease (COVID-19). Rapid global health authorities' responses are now in course and international scientific collaboration is urgently need. Previous outbreaks experiences with similar viral agents have increased the capacity to containment and control of these recurrent health menaces.

Keywords: coronavirus, epidemics, zoonotic, travelers, Colombia

Un nuevo virus zoonótico emergente de preocupación: el Coronavirus novel 2019

Resumen

Revisamos aquí el origen, características del brote y la epidemiología del nuevo Coronavirus (2019nCoV) responsable de una nueva enfermedad por coronavirus (COVID-19). Una rápida respuesta de las autoridades de salud mundiales está en marcha y se ha hecho un llamado urgente para colaboración científica internacional. Las lecciones aprendidas de brotes previos con agentes virales similares han aumentado las capacidades para contener y controlar estas amenazas recurrentes a la salud global.

Palabras clave: coronavirus, epidemias, zoonosis, viajeros, Colombia

Introduction

During the first weeks of 2020, the world has evidenced the emergence of a new human pathogen that achieved the enough zoonotic spillover to cause an outbreak, a third highly pathogenic betacoronavirus¹⁻³. The 2019 novel Coronavirus (2019nCoV), is a new member of a group, that includes previously recognized zoonotic pathogens⁴, as is the case of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), that caused epidemics in China in 2002-2003, and the Middle East Respiratory Syndrome (MERS-CoV), affecting Saudi Arabia and neighbor countries in 2012-2013⁵⁻⁸.

Epidemiology

After the epidemic localized in Wuhan, province Hubei, China, spreading to other cities and provinces of the country, occurred in the following days and weeks, but also to other countries in Asia, Europe, North America and the Pacific regions. Till February 8, 2020, there were 34,945 cases (34,609 in China, 99%), with 336 cases in other 27 countries; 266 cases in the other 15 Asian countries, 26 cases in nine European countries, 12 cases in United States, 7 in Canada, and 15 in Australia (Table 1). Daily updates of these data are found at the Situation Report site of the World Health Organization

1 Centro Médico Imbanaco, Cali, Colombia. President 2019-2021, ACIN.
2 Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnológica de Pereira, Pereira, Risaralda, Colombia. Associate Editor, Infectio. Vicepresident 2019-2021, ACIN.
Committee on Tropical Medicine, Zoonoses and Travel Medicine, Asociación Colombiana de Infectología, Bogotá, DC, Colombia.
3 Department of Pediatrics, Universidad Nacional de Colombia, Bogotá, Colombia. Secretary 2019-2021, ACIN.
Division of Infectious Diseases, Fundación Hospital de la Misericordia, Bogotá, Colombia.
4 Hemera Unidad de Infectología IPS SAS, Bogota, Colombia. Treasurer, 2019-2021, ACIN.
5 Hospital San Vicente Fundación, Medellín, Antioquia, Colombia. Fiscal, 2019-2021, ACIN.

6 Department of Internal Medicine, Faculty of Medicine, Universidad Nacional de Colombia, Bogotá, Colombia. Associate Editor, Infectio.
Clínica Universitaria Colombia, Clínica Colsanitas. Bogotá, Colombia.
* Autor para correspondencia.
Correo electrónico: arodriguez@utp.edu.co
+573008847448

Recibido: 07/02/2020; Recibido con modificaciones: 09/02/2020;
Aceptado: 09/02/2020

Cómo citar este artículo: J. Millán-Oñate, *et al.* A new emerging zoonotic virus of concern: the 2019 novel Coronavirus. Infectio 2020; 24(3)

Table 1. Confirmed cases, deaths and patients recovered during the ongoing 2019-nCoV global outbreak (as February 8, 2020 – 6.00 a.m.), by continents and countries. Sources: WHO, CDC, ECDC, NHC and DXY, via <https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>.

Continent	Number of countries affected	Country	Cases	Deaths	%	Recovered	%
Asia	16	Mainland China	34609	723	2.1	2328	6.7
		Japan Yokohama Bay*	61	0	0.0	0	0.0
		Singapore	33	0	0.0	0	0.0
		Hong Kong	26	1	3.8	0	0.0
		Thailand	25	0	0.0	5	20.0
		Japan	25	0	0.0	1	4.0
		South Korea	24	0	0.0	1	4.2
		Taiwan	17	0	0.0	1	5.9
		Malaysia	16	0	0.0	0	0.0
		Vietnam	13	0	0.0	1	7.7
		Macau	10	0	0.0	1	10.0
		United Arab Emirates	7	0	0.0	0	0.0
		India	3	0	0.0	0	0.0
		Philippines	3	1	33.3	0	0.0
		Nepal	1	0	0.0	0	0.0
		Cambodia	1	0	0.0	0	0.0
Sri Lanka	1	0	0.0	1	100.0		
		Subtotal	34875	725	2.1	2339	6.7
Europe	9	Germany	13	0	0.0	0	0.0
		France	11	0	0.0	0	0.0
		Italy	3	0	0.0	0	0.0
		United Kingdom	3	0	0.0	0	0.0
		Russia	2	0	0.0	0	0.0
		Spain	1	0	0.0	0	0.0
		Finland	1	0	0.0	0	0.0
		Sweden	1	0	0.0	0	0.0
		Belgium	1	0	0.0	0	0.0
		Subtotal	36	0	0.0	0	0.0
Americas	2	US	12	0	0.0	0	0.0
		Canada	7	0	0.0	0	0.0
		Subtotal	19	0	0.0	0	0.0
Oceania	1	Australia	15	0	0.0	2	13.3
Total	28		34945	725	2.1	2341	6.7

(WHO) (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/>)⁹ and at a dedicated website of the John Hopkins University, which reports a number greater than WHO, because it reports online information from several international agencies (<https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>). Other source of digested relevant information is ProMEDmail (<http://www.promedmail.org>), from International Society for Infectious Diseases.¹⁰ Although at the moment, it is not possible to know the lethality, because the real number of infected people is not known, if it is understood that at least the people confirmed with the infection by the novel 2019nCoV, about 2% have died and at least 10% have severe clinical manifestations⁹.

It is highlighted that the cases of China are still concentrated in the province of Hubei; the proportion of cases reported in provinces outside of Hubei (one-third) compared to cases reported in Hubei (two-thirds). So far (February 7, 2020), no cases have been confirmed in Latin America, nor in Colombia, although multiple suspected cases, of people coming from China, especially Wuhan, have been notified and ruled out. On February 4, 2020, the National Institute of Health of Colombia publicly announced that has standardized the RT-PCR to make possible the molecular diagnosis of 2019nCoV.

After the alert to the WHO about the outbreak, a rapid assessment considered the possibility to declare the ongoing situation, as occurred effectively on January 30, 2020, a Pu-

blic Health Emergency of International Concern (PHEIC)^{11,12}. Even more in this setting, countries worldwide should consider the necessary preparedness and response in the front of the potential arrival of imported cases, and as has been also documented, the human-to-human transmission with autochthonous secondary cases^{13,14}. However, currently there is a controversy if human-to-human transmission it is possible from an asymptomatic person, which would complicate outbreak control strategies so far.

Taxonomy

The family Coronaviridae, currently includes two classified subfamilies, Coronavirinae, and the Orthocoronavirinae. This last, has four genera: Alphacoronavirus, Betacoronavirus, Deltacoronavirus, and Gammacoronavirus (Table 2). They compromised the currently seven virus species that affect human beings, two of them at the genus AlphaCoV (HCoV-229E and HCoV-NL63), and the other five, in at least three subgenera of the genus BetaCoV: Embecovirus (HCoV-OC43 and HCoV-HKU1), Sarbecovirus (SARS-CoV), Merbecovirus (MERS-CoV) (Table 2). The 2019-nCoV is still considered an unclassified Betacoronavirus, but preliminary studies found it phylogenetically closely related to SARS, although different; more than 85% identity in such studies linked it with a bat SARS-like CoV¹⁵⁻²⁶.

Clinical Findings

The main clinical findings, reported in the first preliminary studies, include fever (83%-98%), cough (76%-82%), dyspnea (31%-55%), diarrhea (2%-3%), complicated with acute respiratory distress (ARDS) (17%-29%), acute cardiac injury (12%) and renal failure (3%-7%), among others.^{2,27} With outcomes reported in those studies of 11% to 15% of deaths among cases (case fatality rate, CFR)%.^{2,27}

Treatment and Prevention

Although there are previous studies, suggesting the use of certain antivirals, including oseltamivir, remdesivir, lopinavir/ritonavir, and even chloroquine, used for SARS-CoV and MERS-

CoV, still there are no data from clinical trials. A recent study found that Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) *in vitro*²⁸.

In the meantime, prevention and preparedness in countries with no cases, as is the case of Colombia, is of utmost importance. Guidelines, recommendations and technical documents, from the WHO and international and regional societies²⁹⁻³⁵, would be useful for training of healthcare workers about all the relevant aspects of the 2019nCoV but it is key that health authorities and health institutions implement them^{36,37}.

At the same, as this new virus, is a concern for the world (at least it has already had a global economic impact), Latin America and even Colombia, among other regions and countries, Colombia faces an ongoing epidemic of dengue with over 130,000 cases, 1% of them severe, including more than 100 associated-deaths. When considering respiratory tract infections, multiple infectious agents are actively circulating, and will be increasing in the next few months in the region, including, those under surveillance, such as Influenza A (including AH1N1), Influenza B, human metapneumovirus, respiratory syncytial virus, adenovirus, parainfluenza 1, 2, 3 and 4, rhinovirus, bocavirus and enterovirus, among others³⁸⁻⁴⁰.

Recommendations

The best way to prevent infection is to avoid being exposed to this virus. However, as a reminder, CDC always recommends everyday preventive actions to help prevent the spread of respiratory viruses, including: wash the hands often with soap and water for at least 20 seconds, especially after going to the bathroom; before eating; and after blowing your nose, coughing, or sneezing. If soap and water are not readily available, use an alcohol-based hand sanitizer with at least 60% alcohol. Always wash hands with soap and water if hands are visibly dirty. Avoid touching the eyes, nose, and mouth with unwashed hands. Avoid close contact with people who are sick. Stay home when sick. Cover the cough or sneeze with a tissue, then throw the tissue in the trash. Clean and disinfect frequently touched objects and surfaces

Table 2. Current taxonomy of the human relevant coronaviruses. According to the NCBI Taxonomy, National Institutes of Health, USA (<https://www.ncbi.nlm.nih.gov/taxonomy>).

Subfamily	Genus	Subgenus	Species	No rank	
Orthocoronavirinae	Alphacoronavirus	Duvinacovirus	<i>Human coronavirus 229E</i>		
		Setracovirus	<i>Human coronavirus NL63</i>		
	Betacoronavirus	Embecovirus	Betacoronavirus 1	<i>Human coronavirus OC43</i>	
				<i>Human coronavirus HKU1</i>	
		Sarbecovirus	<i>SARS-CoV</i>		
		Merbecovirus	<i>MERS-CoV</i>		
	unclassified Betacoronavirus	<i>2019-nCoV</i>			
	Deltacoronavirus				
	Gammacoronavirus				

using a regular household cleaning spray or wipe. There is no current specific antiviral treatment recommended for 2019-nCoV infection. People infected with 2019-nCoV should receive supportive care to help relieve symptoms. For severe cases, treatment should include care to support vital organ functions^{41,42}. In addition, there have been announcements for the plans for rapid development of vaccines⁴³. Although that, is worthy to say that recent T-cell immunological studies of SARS-CoV have been published, suggesting the potential cross-reactivity of the SARS-CoV-specific immunity against MERS-CoV, which may provide useful recommendations for the development of broad-spectrum vaccines against coronavirus infections⁴⁴.

Additionally, emphasis should be placed on the role and risk of healthcare workers, especially in emergency services, who in the current outbreak have already been affected (including fatal cases). For this reason, very good adherence to the infection control protocols established in the institutions and to the recommendations issued by WHO (<https://apps.who.int/iris/handle/10665/174652>, accessed 17 January 2020) is mandatory.

In the case of Colombia, the National Institute of Health, have developed a technical guide, "Instructions for intensified public health surveillance of probable cases of severe acute respiratory infection due to a new subtype of Coronavirus (2019nCo)".

Based on the national definition for the Unusual Severe Acute Respiratory Infection (USARI or IRAGi in spanish) event (Code 348), the following definition is specified for intensified surveillance: case probable. A patient with a quantified fever greater than or equal to 38 °C and cough, with a severe acute respiratory infection –IRAG– that develops an unusual or unexpected clinical course, especially a sudden deterioration despite adequate treatment, requiring hospitalization (IRAGi-Code 348) and meet at least one of the following conditions: Travel history to Wuhan, Hubei Province, China or other areas with confirmed viral circulation of the new coronavirus (2019-nCoV) in the 14 days prior to the onset of symptoms (see table published in the INS microsite <https://www.ins.gov.co/Paginas/Inicio.aspx> or see table published in the following link <https://www.minsalud.gov.co/salud/publica/PET/Pages/New-Coronavirus-nCoV.aspx>; health worker or other hospital staff who have had close contact, as defined below, with a probable case or confirmed by a new subtype of Coronavirus (2019-nCoV); history of close contact, as defined below, in the last 14 days with a probable or confirmed case with severe acute respiratory infection due to a new subtype of Coronavirus (2019-nCoV).

For the definition of suspected case, this will be valid, till the Ministry of Health of Colombia inform about confirmed viral circulation of the 2019nCoV in the country. Suspected case: person with a history of quantified fever greater than or equal




Figure 1. Number of cases reported in Mainland China, Asia, North America and Europe of the 2019nCoV.

Inserted, the direct-flight destinations from China's capital city Beijing (PEK) and from Bogotá, Colombia (BOG). Available at: <https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>, sources: WHO, CDC, ECDC, NHC and DXY.

to 38 ° C and cough, with a picture of acute respiratory infection (ARI), mild or moderate that does not require hospitalization (ARI for new virus–Code 346), and meets at least one of the following conditions: Travel history to Wuhan, Hubei Province, China or other areas with confirmed viral circulation of the new coronavirus (2019-nCoV) in the 14 days prior to the onset of symptoms (see table published in the INS microsite <https://www.ins.gov.co/Paginas/Inicio.aspx> or see table published in the following link <https://www.minsalud.gov.co/salud/publica/PET/Pages/New-Coronavirus-nCoV.aspx>; health worker or other hospital staff who have had close contact, as defined below, with a probable case or confirmed by a new subtype of Coronavirus (2019-nCoV); history of close contact, as defined below, in the last 14 days with a probable or confirmed case with severe acute respiratory infection due to a new subtype of Coronavirus (2019-nCoV)⁴⁵.

Close contact is defined as: any contact that has provided care to a confirmed case while the case presented symptoms; health workers who did not use the appropriate protective measures, or family members, or people who have other similar physical contact; any contact (<2 meters) that was in the same place (e.g. cohabitation, visits) that a case confirmed while the case presented symptoms; passengers located in a two-seat radius around symptomatic cases during the flight and the crew that has had contact with such cases are considered close contact on a plane⁴⁵.

Finally, a confirmed case is a person who meets the definition of probable case (of this annex) and has a positive result for new coronavirus 2019-nCoV through real-time RT-PCR⁴⁵.

The National Institute of Health as a website with dedicated information on the 2019nCoV (<https://www.ins.gov.co/Noticias/Paginas/Coronavirus.aspx>). For the last update of it, February 9, 6.00 am, there have been 11 “alerts” ruled out. There is also available the notification formats, algorithms for the diagnosis, protocols for the surveillance and the instructive for collection of samples⁴⁶. Internationally, multiple other health agencies and national secretaries are developing and providing publicly similar information^{9,11,12,30-35,41,42,47-55}.

Conclusions

Societies and associations, such as the Colombian Association of Infectious Diseases, should be actively involved, as a scientific core of infectious diseases specialists in the country, in preparedness of the healthcare workers across the countries, with the support of their technical and thematic committees as well as their regional chapters, particularly organizing continuing medical education activities, as such have been organized recently about the 2019nCoV in Bogota and other cities. Also, keep the update of this outbreak, because the information presented today could change with the events that happen in the near future.

Ethical disclosures

Protection of human and animal subjects. This research do not used animal nor human material.

Confidentiality of data. Not applicable

Right to privacy and informed consent. No applicable

Funding. None

Conflict of Interest. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol* 2019;17:181-92.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* 2020 doi 10.1016/S0140-6736(20)30183-5.
3. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. *N Engl J Med* 2003;348:1953-66.
4. Rodriguez-Morales AJ, Bonilla-Aldana DK, Balbin-Ramon GJ, et al. History is repeating itself, a probable zoonotic spillover as a cause of an epidemic: the case of 2019 novel Coronavirus. *Infez Med* 2020;28:3-5.
5. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. *Respirology* 2018;23:130-7.
6. Al-Tawfiq JA, Zumla A, Memish ZA. Travel implications of emerging coronaviruses: SARS and MERS-CoV. *Travel Med Infect Dis* 2014;12:422-8.
7. Al-Tawfiq JA, Gautret P. Asymptomatic Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: Extent and implications for infection control: A systematic review. *Travel Med Infect Dis* 2019;27:27-32.
8. Bonilla-Aldana DK, Quintero-Rada K, Montoya-Posada JP, et al. SARS-CoV, MERS-CoV and now the 2019-novel CoV: Have we investigated enough about coronaviruses? - A bibliometric analysis. *Travel Med Infect Dis* 2020:101566.
9. Novel Coronavirus (2019-nCoV) - Situation report - 10 - 30 January 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200130-sitrep-10-ncov.pdf?sfvrsn=d0b2e480_2_2020.
10. Bonilla-Aldana DK, Holguin-Rivera Y, Cortes-Bonilla I, et al. Coronavirus infections reported by ProMED, February 2000–January 2020. *Travel Med Infect Dis* 2020:101575.
11. Statement on the meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). [https://www.who.int/news-room/detail/23-01-2020-statement-on-the-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-\(2019-ncov\)-2020](https://www.who.int/news-room/detail/23-01-2020-statement-on-the-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)-2020).
12. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). [https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-\(2019-ncov\)-2020](https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)-2020).
13. Phan LT, Nguyen TV, Luong QC, et al. Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. *N Engl J Med* 2020 doi 10.1056/NEJMc2001272.
14. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. *N Engl J Med* 2020.
15. Battilani M, Coradin T, Scagliarini A, et al. Quasispecies composition and phylogenetic analysis of feline coronaviruses (FCoVs) in naturally infected cats. *FEMS Immunol Med Microbiol* 2003;39:141-7.
16. Carrington CV, Foster JE, Zhu HC, et al. Detection and phylogenetic analysis of group 1 coronaviruses in South American bats. *Emerg Infect Dis* 2008;14:1890-3.
17. Kanno T, Kamiyoshi T, Ishihara R, Hatama S, Uchida I. Phylogenetic studies of bovine coronaviruses isolated in Japan. *J Vet Med Sci* 2009;71:83-6.

18. Motokawa K, Hohdatsu T, Hashimoto H, Koyama H. Comparison of the amino acid sequence and phylogenetic analysis of the peplomer, integral membrane and nucleocapsid proteins of feline, canine and porcine coronaviruses. *Microbiol Immunol* 1996;40:425-33.
19. Stephensen CB, Casebolt DB, Gangopadhyay NN. Phylogenetic analysis of a highly conserved region of the polymerase gene from 11 coronaviruses and development of a consensus polymerase chain reaction assay. *Virus Res* 1999;60:181-9.
20. Sun C, Han Z, Ma H, et al. Phylogenetic analysis of infectious bronchitis coronaviruses newly isolated in China, and pathogenicity and evaluation of protection induced by Massachusetts serotype H120 vaccine against QX-like strains. *Avian Pathol* 2011;40:43-54.
21. Yip CW, Hon CC, Shi M, et al. Phylogenetic perspectives on the epidemiology and origins of SARS and SARS-like coronaviruses. *Infect Genet Evol* 2009;9:1185-96.
22. Zhang SF, Tuo JL, Huang XB, et al. Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in Guangzhou. *PLoS ONE* 2018;13:e0191789.
23. Zhang XM, Kousoulas KG, Storz J. The hemagglutinin/esterase gene of human coronavirus strain OC43: phylogenetic relationships to bovine and murine coronaviruses and influenza C virus. *Virology* 1992;186:318-23.
24. Revision of the taxonomy of the Coronavirus, Torovirus and Arterivirus genera. *Arch Virol* 1994;135:227-37.
25. Wang Y, Liu D, Shi W, et al. Origin and Possible Genetic Recombination of the Middle East Respiratory Syndrome Coronavirus from the First Imported Case in China: Phylogenetics and Coalescence Analysis. *mBio* 2015;6:e01280-15.
26. Wang Y, Liu D, Shi W, et al. A47 Origin and possible genetic recombination of the middle east respiratory syndrome coronavirus from the first imported case in china: phylogenetics and coalescence analysis. *Virus Evol* 2017;3.
27. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* 2020 doi 10.1016/S0140-6736(20)30211-7.
28. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Research* 2020.
29. Biscayart C, Angeleri P, Lloveras S, Chaves T, Schlegelhauf P, Rodriguez-Morales AJ. The next big threat to global health? 2019 novel coronavirus (2019-nCoV): What advice can we give to travellers? - Interim recommendations January 2020, from the Latin-American society for Travel Medicine (SLAMVI). *Travel Med Infect Dis* 2020:101567.
30. ECDC. Advice to healthcare workers: management of patients with 2019-nCoV infection 2020. <https://www.ecdc.europa.eu/en/publications-data/advice-healthcare-workers-management-patients-2019-ncov-infection>.
31. ECDC. Algorithm for management of contacts of probable or confirmed 2019-nCoV cases 2020. <https://www.ecdc.europa.eu/en/publications-data/algorithm-management-contacts-probable-or-confirmed-2019-ncov-cases>.
32. ECDC. Infection prevention and control for the care of patients with 2019-nCoV in healthcare settings 2020. <https://www.ecdc.europa.eu/en/publications-data/infection-prevention-and-control-care-patients-2019-ncov-healthcare-settings>.
33. ECDC. Public health management of persons having had contact with novel coronavirus cases in the European Union 2020. <https://www.ecdc.europa.eu/en/publications-data/public-health-management-persons-having-had-contact-novel-coronavirus-cases>.
34. Communicating risk in public health emergencies: a WHO guideline for emergency risk communication (ERC) policy and practice. <https://www.who.int/risk-communication/guidance/download/en/>. 2017.
35. Pneumonia of unknown cause – China. <https://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en/>. 2020.
36. Rodríguez-Morales AJ, MacGregor K, Kanagarajah S, Patel D, Schlegelhauf P. Going global – Travel and the 2019 novel coronavirus. *Travel Med Infect Dis* 2020:101578.
37. Arteaga-Livias FK, Rodriguez-Morales AJ. La comunicación científica y el acceso abierto en la contención de enfermedades: El caso del Coronavirus novel 2019 (2019-nCoV). *Rev Peru Investig Salud* 2020;4:7-8.
38. Ali A, Lopardo G, Scarpellini B, Stein RT, Ribeiro D. Systematic review on respiratory syncytial virus epidemiology in adults and the elderly in Latin America. *Int J Infect Dis* 2020;90:170-80.
39. Bernal LJ, Velandia-Romero M, Guevara C, Castellanos JE. Human Metapneumovirus: Laboratory Methods for Isolation, Propagation, and Plaque Titration. *Intervirology* 2018;61:301-6.
40. Evelyn O, Jaime FS, David M, Lorena A, Jenifer A, Oscar G. Prevalence, clinical outcomes and rainfall association of acute respiratory infection by human metapneumovirus in children in Bogota, Colombia. *BMC Pediatr* 2019;19:345.
41. 2019 Novel Coronavirus - Prevention & Treatment. <https://www.cdc.gov/coronavirus/2019-ncov/about/prevention-treatment.html>. 2020.
42. 2019 Novel Coronavirus - Information for Healthcare Professionals. 2020. <https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html>.
43. Hunecutt B, Lurie N, Rotenberg S, Wilder R, Hatchett R. Finding equipoise: CEPI revises its equitable access policy. *Vaccine* 2020.
44. Liu WJ, Zhao M, Liu K, et al. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. *Antiviral Res* 2017;137:82-92.
45. Instructivo para la vigilancia en salud pública intensificada de casos probables de infección respiratoria aguda grave por nuevo subtipo de Coronavirus (2019-nCoV). https://www.ins.gov.co/Noticias/Coronavirus/Anexo_Instructivo%20para%20la%20vigilancia%202019-nCoV%20Colombia.pdf. 2020.
46. Coronavirus en Colombia. <https://www.ins.gov.co/Noticias/Paginas/Coronavirus.aspx>. 2020.
47. ECDC. ECDC statement following reported confirmed case of 2019-nCoV in Germany 2020. <https://www.ecdc.europa.eu/en/news-events/ecdc-statement-following-reported-confirmed-case-2019-ncov-germany>.
48. Novel coronavirus. 2020. <https://www.ecdc.europa.eu/en/novel-coronavirus-china>.
49. ECDC. Risk assessment: Outbreak of acute respiratory syndrome associated with a novel coronavirus, China: first local transmission in the EU/EEA – third update 2020. <https://www.ecdc.europa.eu/en/publications-data/risk-assessment-outbreak-acute-respiratory-syndrome-associated-novel-1>.
50. Novel Coronavirus (2019-nCoV) - Situation report - 4 - 24 January 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200124-sitrep-4-2019-ncov.pdf?sfvrsn=9272d086_2. 2020.
51. Novel Coronavirus (2019-nCoV) - Situation report - 7 - 27 January 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200127-sitrep-7-2019-ncov.pdf?sfvrsn=98ef79f5_2020. 2020.
52. List of Blueprint priority diseases. 2018. (Accessed 4-4-2018, at www.who.int/blueprint/priority-diseases/en/).
53. International Tourism Highlights, 2019 Edition. 2019 doi 10.18111/9789284421152
54. China travel advice. <https://www.gov.uk/foreign-travel-advice/china>. 2020.
55. Health - China travel advice. <https://www.gov.uk/foreign-travel-advice/china/health>. 2020.